Literature DB >> 8398695

MDR1 gene expression in primary colorectal carcinomas.

R Pirker1, J Wallner, A Gsur, M Götzl, S Zöchbauer, W Scheithauer, D Depisch.   

Abstract

The expression of the MDR1 gene, a multidrug resistance gene, was prospectively determined in 113 primary colorectal carcinoma specimens and correlated with clinical data including survival durations of the patients. MDR1 RNA was detected in 65% of the carcinomas. No expression of the MDR2 gene was seen, MDR1 gene expression was independent of age and sex of the patients, size and histologic grading of the tumour, lymph node involvement and distant metastasis. Kaplan-Meier analysis revealed that the durations of both relapse-free survival and overall survival were not different between patients with MDR1 RNA positive tumours and those with MDR1 RNA negative tumours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398695      PMCID: PMC1968613          DOI: 10.1038/bjc.1993.411

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 3.  Multiple-drug resistance in human cancer.

Authors:  I Pastan; M Gottesman
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

Review 4.  The multidrug transporter, a double-edged sword.

Authors:  M M Gottesman; I Pastan
Journal:  J Biol Chem       Date:  1988-09-05       Impact factor: 5.157

5.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

6.  Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines.

Authors:  J R Riordan; K Deuchars; N Kartner; N Alon; J Trent; V Ling
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

7.  Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

Authors:  A T Fojo; D W Shen; L A Mickley; I Pastan; M M Gottesman
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

8.  P-glycoprotein in human sarcoma: evidence for multidrug resistance.

Authors:  J H Gerlach; D R Bell; C Karakousis; H K Slocum; N Kartner; Y M Rustum; V Ling; R M Baker
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

9.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

Authors:  D R Bell; J H Gerlach; N Kartner; R N Buick; V Ling
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

10.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

Authors:  I B Roninson; J E Chin; K G Choi; P Gros; D E Housman; A Fojo; D W Shen; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

View more
  9 in total

1.  Dexverapamil as resistance modifier in acute myeloid leukaemia.

Authors:  R Pirker; S Zöchbauer; H Kupper; A Lassmann; A Gsur; M Frass; G Krajnik; P Knöbl; K Lechner
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.

Authors:  M Fillpits; R W Suchomel; G Dekan; W Stiglbauer; K Haider; D Depisch; R Pirker
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 3.  Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

Authors:  G-T Ho; F M Moodie; J Satsangi
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

4.  Decreased functional activity of multidrug resistance protein in primary colorectal cancer.

Authors:  Tamás Micsik; András Lőrincz; Tamás Mersich; Zsolt Baranyai; István Besznyák; Kristóf Dede; Attila Zaránd; Ferenc Jakab; László Krecsák Szöllösi; György Kéri; Richard Schwab; István Peták
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

Review 5.  The Roles of MicroRNAs in Breast Cancer.

Authors:  Ryou-U Takahashi; Hiroaki Miyazaki; Takahiro Ochiya
Journal:  Cancers (Basel)       Date:  2015-04-09       Impact factor: 6.639

6.  P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers.

Authors:  M Oka; K Kounoura; F Narasaki; A Sakamoto; M Fukuda; I Matsuo; K Ikeda; J Tsurutani; N Ikuno; K Omagari; Y Mizuta; H Soda; J M Gudas; S Kohno
Journal:  Jpn J Cancer Res       Date:  1997-08

Review 7.  Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.

Authors:  Jose J G Marin; Maria J Monte; Rocio I R Macias; Marta R Romero; Elisa Herraez; Maitane Asensio; Sara Ortiz-Rivero; Candela Cives-Losada; Silvia Di Giacomo; Javier Gonzalez-Gallego; Jose L Mauriz; Thomas Efferth; Oscar Briz
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

8.  P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo.

Authors:  P De Angelis; T Stokke; L Smedshammer; R A Lothe; G Lehne; Y Chen; O P Clausen
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

9.  The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models.

Authors:  C Martin; J Walker; A Rothnie; R Callaghan
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.